Focus Surgery Seeks IDE For Sonablate HIFU Prostate Cancer Treatment
This article was originally published in The Gray Sheet
Executive SummaryFocus Surgery says it will file an investigational device exemption application with FDA in mid-to-late 1999 to begin U.S. clinical trials of the Sonablate 200 high-intensity focused ultrasound (HIFU) system for treatment of prostate cancer.
You may also be interested in...
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.